COVID-19 Notice

In the current context of the global health crisis, like you, we are committed to acting for health prevention and citizens’ care, and everyone’s safety is our priority.

We remain very attentive to the developments in the situation, in particular those on the rules and instructions relating to gatherings such as our international event BioTech Pharma Summit.
In this very special period, you can always count on our commitment to support you in the best conditions to prepare for the upcoming edition of BioTech Pharma Summit.

During the movement and gathering behaviour restriction, our teams are teleworking at home in order to ensure our service continuity, while ensuring everyone’s safety. We therefore remain available and reachable by e-mail only.

Meanwhile at the conference, we are currently working together with the Portuguese government and health authorities in order to proceed seamlessly with the conference, respecting all the protocols (e.g Free provided masks and sanitizers, distance between delegates, temperature measurements and limited audience).

While it’s unlikely that masks will be legally required indoors in Portugal by November, BioTech Pharma Summit will remain supportive of any attendee who wishes to wear a mask.

We require all participants to show a negative COVID-19 test result performed within 72 hours prior to the time of the event OR COVID-19 vaccination certificate.

We thank you for your understanding and consideration, and we sincerely hope to welcome you to the next edition of BioTech Pharma Summit on November 29 and 30, 2021 in Porto, Portugal.

In these difficult and uncertain times, our thoughts are with you and all medical and nursing staff.
Let’s take care of each other

The BioTech Pharma Summit team


EPM Group events are carefully designed to answer critical aspects of business development and followed by in-depth research analysis that complies with the current market and business leaders’ needs. The goal of our events is to implement new strategies and increase your experience and professional skills by networking, benchmarking and generating insights from industry leaders.

New trends, Innovations, Modern technologies, New products, Emerging topics are generated for senior level executives to provide a cutting edge of business information and maximum return of investment for our clients from different areas on the Pharmaceutical industry.

Our team of professionals and experts provides information focused on business strategies that will encourage the competitive advantage of our clients at which they achieve their objectives. EPM team maintains the highest standards of quality and service in research, technology and product development.

Choose your stream


Antibody Engineering & Therapeutics


The Antibody Engineering & Therapeutics will provide the latest science, technology and partners to accelerate antibody & protein therapies, ADCS, Bispecifics and Immuno-Oncology.

The global next-generation antibody therapeutics market size was valued at USD 3.83 billion in 2019. This figure is expected to grow at a CAGR of 13% and will reach USD 7.06 billion by 2024.

The next-generation antobody therapeutic is majorly driven by the development of monoclonal antibodies and frowing chronic diseases prevalence. The increasing population, urbanization, and changing lifestyle are favouring the anti-generation antibody therapeutics market growth. Increasing government supports through investments and focus of the pharmaceutical & biotechnology firms on the development of antibodies for future usage of chronic disease are further accelarating the next generation therapeutic market.

The increasing development in the ADCs technology and collaboration are raised the market growth of the next generation antibody therapeutics market. The techologies such as artificial intelligence in the form of software it can lead the product innovation with effective result drive the market

The Summit will shed light on the progress in discovery, development and therapeutics of novel protein therapeutics, and the latest breakthrough engineering next-generation antibody formats. The conference offers a unique opportunity to reach the pre-eminent researchers working in his important field of science from both the industry and academic sectors.

Key Practical learning Points

  • Bioinformatics and Repertoires in Antibody Discovery and Development
  • Antibody Discovery and Developability
  • Intractable Targets/ Antibody Discovery Technologies
  • Novel Antibody-based Therapeutics for Cancer & Immuno-oncology
  • Antibody Effector Functions and Novel Formats
  • New Antibody Therapeutics in Inflammatory & Infectious Diseases
  • Antibodies Alternative Delivery/Vaccines
  • CAR-T & anti-CD3-based Bispecifics
  • The Nuts and Bolts of Antibodies
  • CMC strategies for developing manufacturing processes and product quality characterization of bispecifics / multispecifics
  • Emerging approaches, science and tech to engineer and to bring to market more targeted, stable extended half-life, and functional multispecifics
  • Advanced analytical development and characterization for novel protein formats
  • Imaging, theranostic, and other new applications of bispecifics in oncology and beyond
  • Accelerating translation and clinical development progress of bispecific antibody and combination therapies
  • Turning Antibody Leads into Drugs
  • Antibody Selection and Screening in Early Discovery
  • Antibody Binding Sites as Therapeutics: scFv, VHH, VNAR and beyond
  • Transforming Therapeutics Targets
  • Developments in ADC Tecnhology
  • Inducible Activation of Antibodies to Enhance Therapeutic Index
  • Responding to the COVID-19 Pandemic with Antibodies, Small Molecules Drugs and Vaccines
  • Sourcing Disease-specific Human Antibodies from Patient Repertoires.
  • Antibody Therapeutics for Autoimmune and Neurodegenerative Diseases
  • Expressing Antibodies by Gene Therapy and/or Viral Therapies
  • Bispecific Formats for T Cell Activation
  • Novel Insights into Immunoglobulin Structures
  • Computational Modeling of Anibody-Antigen Interations
  • FcR and Antibody Effector Functions
  • Novel non-Cancer Targets for Therapeutics Antibodies.
  • Modifying Fc Interactions to Enhance Antibody Therapies.
  • Potentiating Antibodies through Conjugation

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • Antibody Discovery
  • Analytical & Formulation
  • Bioassay
  • Biologics
  • Cancer
  • CD3
  • Clinical trials / Development
  • Central Nervous System (CNS) / Neuroscience
  • Drug Development
  • EGFR
  • Fc
  • Genetics
  • Immunogenicity
  • In Silico Modelling / Quantitative Science
  • Ex Vivo Assay
  • FIH
  • Process Development / Developability
  • Protein Chemistry
  • T-cell
  • Theranostics
  • Toxicities / Toxicology
  • Yield
  • Antibody Engineering
  • Blood Brain Barrier
  • Biochemistry
  • Bispecifics
  • Cancer Immunotherapies
  • Checkpoint
  • CMC / Regulatory
  • Combination Therapies
  • Drug Targets / Targets Selection
  • Preclinical Models
  • Imaging
  • Immunology
  • Mab
  • Monoclonal Antibodies
  • Neuroscience
  • Pharmacokinetics (PK)
  • Process / Manufacturing Quality
  • Protein
  • Screening / Modelling
  • Target Toxities
  • Therapeutic Antibodies
  • Tumours
  • Manufacturing
  • Multispecific Antibody
  • Oncology


Inhalation & Respiratory Drug Delivery


The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market. The agenda also features key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy.

A recent report from the Pharmaceutical Research and Manufacturers of America (PhRMA) found America’s biopharmaceutical companies are developing about 130 new medicines for the millions of patients affected by respiratory diseases: chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, and asthma. These medicines represent critical advancements in respiratory care and improving quality of life. In addition to the drugs, devices delivering those products are being designed to improve the quality of life for an aging population, children, and those who tend not to comply to dosing regimens because they don’t know how to use the device. The global respiratory care devices market is expected to exceed more than $24 billion by 2022,2 and could exceed $33 billion by 2023.

This stream will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled insulin to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis. The event highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.

Key Practical learning Points

  • Novel technologies for pulmonary & nasal delivery
  • Modern respiratory medicines
  • Innovative development of inhalation devices
  • Digital health combination products
  • Analytical tools for inhaled medicines
  • Challenges of bringing inhalation and respiratory drug delivery products to market
  • Regulatory updates in the global respiratory market
  • The challenges of developing inhalation devices
  • Alternative therapeutic fields
  • Innovation in nebulised therapy
  • Triple inhaler therapy in COPD
  • Inhaled drugs through functional respiratory imaging (FRI) and artificial intelligence (AI)
  • Dry-powder inhalers (DPIs) and Metered-dose inhalers (MDIs)
  • New analytical insights into dry powder formulations for inhalation
  • Routes to controlling aerosol response
  • Characterizing aerosol dynamics
  • Model validation
  • Future directions in inhalation and respiratory drug delivery research
  • Regulatory pathways for inhaled therapies
  • Strategies for Managing the Impact of Brexit
  • Challenges of developing a generic inhaled product
  • Explore opportunities with smart and digital inhalers

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • Respiratory Drug Development
  • Generics & Respiratory
  • Inhalation Drug Delivery Technologies
  • Device Development and Engineering
  • Respiratory Pharmacology
  • Medical Devices & Injectors
  • Inhalation Device Development
  • Inhaled Formulation Science
  • Inhalation Product Development
  • Respiratory Regulations
  • Generics & Respiratory
  • Inhalation Process Development
  • Respiratory Medicine
  • Inhalation Drug Delivery
  • E-Health
  • Inhaled Dosage Forms
  • Outsourcing
  • Process Development
  • Respiratory Pharmacology
  • Device Engineering
  • Drug Delivery Innovation
  • Inhalation Devices
  • Metered Dose Inhaler Development
  • Medical Marketing
  • Respiratory R&D
  • Particle Characterisation
  • Business Development
  • New Delivery Technologies
  • Connective Health
  • Respiratory Regulations
  • Pulmonary Disease
  • Inhalation
  • Scientific Research


Pharmacovigilance & Drug Safety


The Pharmacovigilance & Drug Safety event is designed to bring you a unique opportunity to gain fresh insights into the common issues faced in the industry, highlighting the areas with the need to focus on in order to remain compliant. Moreover this conference stream will bring-forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.

With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment method and drug.

Pharmacovigilance & Drug Safety event will give you the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs, rather than the cookbook approaches often presented elsewhere. In addition to new developments and updates on regional regulations and guidelines, regulators from the US, EU, and other global regions provide the context and thinking behind evolving requirements. The summit will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and contribute to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field.

Key Practical learning Points

  • Impacts of PV on Covid-19
  • Improving Signal surveillance
  • Artificial Intelligence in Signal Detection
  • Combination products – Regulation, trials, and risk management
  • The role of data mining in Pharmacovigilance and its benefits
  • IDMP standards and strategy
  • Developing a pharmacovigilance risk management plan with a risk minimization action plan (RiskMAP) for high risk products
  • Understanding how Artificial Intelligence is transforming pharmacovigilance
  • Evaluation of quality and manufacturing in production
  • Audits and Inspections
  • Strengthening Pharmacovigilance quality management system
  • Impact of AI in Pharmacovigilance
  • Upcoming regulatory changes
  • Signal management
  • Application of data analytics in Pharmacovigilance processes to increase speed of signal detection
  • Cooperation for patients safety
  • Development and deployment of advanced data management systems
  • Does AI have a real role to play in PV?
  • The role of surveys in controlling the overall risk management system
  • Proactive vs. predictive technologies in the future of PV
  • Brexit and the impact on pharmacovigilance
  • Strategies to improve PV
  • Real World Evidence in PV
  • Best practices for developing an overall PV audit strategy with a business partner
  • Is there a way to effectively and reliably use social media towards a QPPV’s end goals?
  • Real-time drug safety data analysis in medical monitoring
  • How has inspection preparation changed and what are the new methods on the horizon?
  • Big data and AI in pharmacovigilance
  • Pharmacovigilance Monitoring and automation in Social media

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • QPPV
  • Risk Management
  • Pharmacoepidemiology
  • Signal Detection
  • Pharmacovigilance
  • Risk Assessment
  • Market Research Programs
  • PV Governance
  • Phase IV/Postmarketing Safety
  • Drug Safety
  • Patient Safety
  • Medical Affairs
  • Quality Assurance
  • Regulatory Affairs
  • Audit Readiness
  • Medical Safety
  • Safety Surveillance


Pre-filled Syringes & Injectables


The Pre-Filled Syringes conference will bring together all specialists in medical devices and pharmaceuticals to share experience about new technology trends, design considerations, technical developments of quality and materials in pre-filled syringes. The conference will provide a comprehensive overview for market participants to overcome common industry hurdles and gain knowledge in key areas surrounding chemical compatibility, E&L; needle safety; human factors and home-based administration and compliance.

The global market revenue fo prefilled syringes grossed $4.9bn (€4.4bn) in 2018 and is estimated to exceed $9.7bn by 2025. The market driver of the highest stature for the global prefilled syringes market growth is the increase in chronic ailments and demand for advanced medical facilities. The rise in diabetes, cancer, and cardiovascular disorders is also causing market growth. Other important market drivers are increasing research & development (R&D), demand for convenient drug delivery methods, elimination of dosing errors, need for more effective methods for unit dose medication, greater dose precision, suitability for home use, and initiatives from different governments around the world to boost healthcare sector.

The Pre-Filled Syringes & Injectables event will explore the advancements in regulatory guidelines, product development, manufacturing processes, risk mitigation, portfolio management and answer some infinite industry questions such as; how the industry is responding to disruptive technology, connectivity, speed to market, and next generation syringes.

Key Practical learning Points

  • Current market developments, trends, and needs for Pre-Filled Syringes (PFS)
  • The latest technologies in materials and production process development
  • Navigating regulatory considerations in the PFS market environment
  • New drug formulation strategies
  • Syringe filling of high-concentration monocolonal antibody formulation
  • Human factor and usability engineering for patient-centric
  • Drug-device combination products development challenges
  • Safety evaluation of leachables when developing a pre-filled syringe drug product
  • Next generation design and materials for PFS
  • Challenges of platformization
  • Combination products and auto injectors
  • Technical developments to enhance device quality
  • Sterile manufacturing
  • Ensuring efficient drug development
  • Human-factors engineering and usability
  • Patient centric design considerations for PFS
  • Overview of the upcoming EU MDR regulation, the role of notified bodies
  • The Impact of 21 CFR 4 on design control
  • Patient-Centric dosage form design
  • Digitalization
  • Integrating Quality Requirements
  • Implementation of novel technologies
  • Manufacturing of sterile injectable drugs
  • Analytical studies and chemical safety assessment
  • Smart labeling solutions for pre-filled syringes

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • Bioprocess Research and Development
  • Business Development
  • CMC
  • Combination Products
  • Container Development
  • Controls and Robotics
  • Device Development & Manufacturing
  • Device Engineering & Design
  • Drug Delivery & Devices
  • Formulation Sciences
  • Research and Development
  • Risk Management
  • Stability
  • Standardisation science
  • Sterile Products
  • Vaccines
  • Validation
  • Extractables & Leachables
  • Fill/Finish
  • External Supply
  • Human Factors
  • Injectables
  • Materials Development
  • Medical & Connected Devices
  • Parenterals
  • PFS
  • QA/QC
  • Regulatory AffairsDrug Development
  • Drug Packaging


Gut-Brain Axis


The Gut-Brain Axis event, brings together leading scientists, physicians, and senior leaders to explore the potential insights into the Microbiota–Gut–Brain Axis, the Human Microbiome Market that exhibits significant potential in the near future.

The ability of gut microbiota to communicate with the brain is emerging as an exciting concept in health and disease. Mounting evidence, mostly from rodent studies, suggests that gut microbes help shape normal neural development, brain biochemistry, and behaviour.

The Gut-Brain Axis will be dedicated to help large pharma, biotech, academics and clinicians exploring and understand the Human Microbiome Market, GBA in demonstrating disease causation. Over the last decade, the microbiome has become one of the trendiest areas of biology, and the research has made clear that the microbiome is fundamental to overall health.

Key Practical learning Points

  • The influence of the intestinal microbiome on vaccine responses
  • Effectively understand and manipulate the Gut-Brain Axis
  • Learn about the microbiota and their metabolites and neurotransmitters production
  • Influence of the microbiota on vaccine effectiveness
  • Discover tools and technologies to help investigate the GBA
  • Build predictive pre-clinical models in the gut-brain axis
  • The importance of the gut–brain axis in emotional, behavioral and development disorders
  • Stress related bowel disease: gut-brain axis in IBD and IBS
  • Develop commercially viable therapeutics and nutritional products
  • Probiotics, prebiotics, synbiotics and psychobiotics

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • Scientific Project Leader
  • Head Search & Evaluation Neuroscience
  • Molecular Toxicology
  • Nutrition & Health
  • Laboratory Director
  • Neuroscientist
  • Regulatory Affairs
  • Modeling and Data Specialist
  • Microbiome and Lipid Biology
  • Genome Editing
  • Business Develoment
  • Associate Research Director
  • Strategy & Business
  • IVD Assay Development
  • Safety Risk Lead
  • Skin & Health
  • Preclinical Group Leader
  • Pharmacovigilance
  • Drug Discovery
  • Research Investigator


Probiotics, Human & Skin Microbiome


The Probiotics, Human & Skin Microbiome event, brings together leading scientists, physicians, and senior leaders to explore the potential insights into the Probiotics, Human & Skin Microbiome that exhibits significant potential in the near future. The event will showcase Industry Case Studies and regulatory insights of the skin microbiome and its impact on cutaneous structure in healthy, aged and compromised state as well as integrated approaches that has been used in human gut microbiome research.

Probiotics as a key functional ingredient in targeting major skin concerns (acne, blemishes, wrinkles etc) is gaining popularity in research, with increasing clinical evidence pointing towards their efficacy. Probiotics – products containing live bacteria – comprise of only a small portion of commercialized cosmetic products and hold great untapped potential in the skincare market. However, implementing live bacteria into mainstream products is not easy. Bacterial products require aseptic conditions, a challenge for packaging, and often have a short shelf life so do not last long.

The current skin microbiome market is dominated by Western countries, with Europe and US being the two largest consumers of cosmetics, but the Asian and Latin American regions are rapidly growing, and a shift is expected within the coming years. The growth of the market only emphasises the huge opportunities for companies working in the skin microbiome space.

This year’s agenda will aim to examine the latest scientific, technological and commercialisation trends in the industry. Presentations will cover topics such as skin health, wellbeing and skin microbiome- associated disease, emerging technologies in the skin microbiome field and cosmetic versus therapeutic regulatory considerations. Don't miss the opportunity to join leading industry experts to explore next steps for skin microbiome research and development, as well as commercialization.

Key Practical learning Points

  • Skin Disease & Microbiome
  • The impact of environment and age on shaping our individual microbiota
  • The skin microbiome: Current perspectives and future challenges
  • Preservative Free-Formulation, Manufacturing and Packing
  • The Skin Microbiome & Big Data
  • Metabolites & Skin Microbiome
  • The Development and Maintenance of the Skin Barrier
  • Learn from research applied to atopic dermatitis, seborrheic dermatitis, fungal-associated diseases and co-infecting microbes that promote chronic wound infection
  • Build on existing partnerships and create new collaborations across industry & academia
  • Commercialization of Microbiome-Based Personal Care
  • Human Skin Microbiome: From metagenomes to therapeutics
  • Regulation considerations for dermatology & cosmetics
  • The applications of L. reuteri DSM 17938 in skin health
  • Commercialising the Therapeutic Potential of The Microbiome in the Field of Metabolic Diseases
  • Discover the latest research into commensal fungi of the mammalian skin
  • Assess the role of the human skin microbiome in precision health
  • Get the latest insights on successful strategies to commercialise Skin Microbiome Research
  • Discover how electrogenic skin bacteria will become novel probiotics for treatments of human diseases
  • Explore a radical shift in the beauty industry, which is seeking to be increasingly pro-bacterial

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • Scientific Project Leader
  • Academic Researchers
  • Molecular Toxicology
  • Nutrition & Health
  • Laboratory Director
  • Independent Beauty Brands
  • Regulatory Affairs
  • Modeling and Data Specialist
  • Microbiome and Lipid Biology
  • Genome Editing
  • Business Develoment
  • Associate Research Director
  • Strategy & Business
  • Dermatologists
  • Safety Risk Lead
  • Skin & Health
  • Preclinical Group Leader
  • Cosmetic Formulators
  • Ingredients Suppliers
  • Research Investigator
  • Packaging Manufacturers


Aseptic Processing Technology


Aseptic Processing Technology event will overview regulatory updates and their implementation, main challenges and overcome consideration, new technologies and innovations to avoid mistakes and ensure safe highly potent aseptic production for both sides - manufacturer and patient. This event will help you improve your aseptic processes and address contamination control issues that you may encounter.

The aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs, pragmatic barrier system applications, adaptability and modularity in fill finish, robotics and automation, small and agile product manufacturing, just to name a few. In 2018, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027, with a CAGR growth of 9.18%.

At the event you will have the opportunity to discourse and to network with peers involved in pharmaceutical manufacturing, aseptic fill and finish, quality control, engineering, and container development. Key topics in Aseptic Processing will be discussed by some of the industry’s leading lights.

During this event, you will learn about environmental monitoring systems, facility cleaning and disinfectant qualification, aseptic cleanroom operations, filtration, sterilization, aseptic process simulation, and regulatory requirements. Hands-on activities will include gowning qualification, facility cleaning and disinfection, aseptic technique qualification, aseptic process simulation, and microbial identification.

Key Practical learning Points

  • The Evolution of Aseptic Technologies
  • Multi-Product facilities
  • Regulatory framework. Aseptic Processing principles.
  • Antibody Drug Conjugates / HPAPIs production
  • Lyophilization of highly potent products and aseptic processing.
  • Occupational safety requirements
  • Aseptic process development, validation and evaluation.
  • Aseptic processing simulation
  • Highly potent facility design and engineering considerations
  • Isolator Technology use in aseptic processing for loss minimization/elimination.
  • Overcoming technical challenges in decontamination processes and material transfers.
  • Cleaning and disinfection programs for aseptic facilities.
  • Microbiology concepts and techniques
  • Cross contamination prevention and control for highly potent products.
  • Robotics in aseptic processing
  • Gloveless Isolators and dose control
  • Final fill with SU Equipment
  • ADC/HPAPI aseptic processing fill and finish
  • Challenges for manufacturers in cell and gene therapy production systems
  • Airflow visualization for contamination risks assessment.
  • Implementing containment technologies in aseptic processing
  • Boosting sterilization: successful strategies, advanced technologies implementation.
  • Cleaning automation and technologies.
  • Gowning: procedures, training, personnel qualification.
  • Microbiology techniques use in aseptic processing.
  • Integrating sanitization techniques to empower contamination control.
  • Filtration: filter integrity testing in aseptic processing.
  • Single-use systems implementation.
  • Assess airflow visualization to limit risk for product contamination
  • Describe the importance of filter integrity testing for aseptic operations
  • Cleanrooms for the Annex 1 updates
  • Implementation of quality risk management

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists, Medical Doctors of/and:

  • Bioprocess Research
  • and Development
  • Biotechnology
  • Container Development
  • CMC
  • Drug Development
  • Engineering
  • Fill and Finish
  • Freeze-Drying
  • Formulation
  • Medical Devices
  • Nanomaterials
  • Parenterals
  • Packaging and Labelling
  • Pharmaceutical Process and Technology
  • Process Monitoring and Control
  • Process Analytics
  • Product Innovation
  • Packaging
  • QA/QC
  • R&D
  • Risk Management
  • Regulatory Affairs
  • Stability
  • Standardisation Science
  • Sterilisation
  • Vaccine/Antibody/Cell Manufacturing
  • Validation
  • Licensing
  • Lyophilisation


CDx/Biomarkers & Biobanking


The CDx/Biomarkers & Biobanking event will bring together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, Biobanking and leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the conference a perfect meeting-place to share experience, foster collaborations across industry and academia, evaluate emerging technologies and all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.

CDx market is growing due to continuous advancement in medical technology both for the diagnosis and the treatment of patients. Rise in the prevalence of diseases like cancer & HIV is fueling to the growth of companion diagnostics as it assist in determining the patient specific dose and drugs. The Biomarkers Market is expected to register a CAGR of 10.28% during the assessment period of 2020 to 2027, to reach USD 4,5B by 2027. With an increasing incidence rate of chronic and life-threatening diseases, the demand for precise diagnostic procedures is increasing. In addition to that, there is an increase in the number of manufacturers, distributors, and service providers of biomarkers across the globe, creating enormous growth opportunities in the market.

Beyond the CDx & Biomarkers, this conference will also gather biobanking leaders from the north Europe, as well as from across the Atlantic, in order to zoom in the market prospects and understand the dynamics of this fast-paced growing industry. Geographically, the EMEA region is estimated to account for a market share of approximately 44% during the predicted period. The presence of a well-established biobanking system in the Nordic countries, such as Sweden, Norway, Denmark, Finland, and Iceland, is a significant factor that bolsters market growth in this region.

The CDx, Biomarkers & Biobanking event will insight into how the biobanking industry at the forefront at driving precision medicine and the opportunities and challenges of biomarker research discovery and development in a variety of therapeutic areas such as immune-oncology, neuroscience and cardio vascular disease areas, precision medicine, companion diagnostics, data integration methods, and utilising biomarkers in clinical trials. We will also cover the most relevant hot topics including: biospecimen science, management, and applications, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge biomedical research, leading to the goal of personalized medicine.

Key Practical learning Points


  • Learn the recent advances and future perspectives in CDx & Biomarkers
  • Understand the key aspects & challenges of Clinical Biomarker development & qualification Solutions for clinical development of precision therapies
  • Predictive Biomarkers and Companion Diagnostics for Immuno-Oncology
  • Proteomics and Genomics based Biomarkers
  • Epigenetic biomarkers in saliva
  • Regulatory landscapes for biomarkers and diagnostic tests
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Main barriers to progression of precision medicine in drug development
  • The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
  • Options for biomarker based patient stratification in NON-ONCOLOGY clinical development
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases
  • Key trends in targeted and immuno-oncology companion diagnostics
  • Clinical applications of liquid biopsies
  • Genomics challenges from a single sample to large clinical studies
  • Tissue Microarray Technology for Biomarker Validation and Discover
  • Design of clinical trials in CDx


  • How AI and biobanks address global challenges
  • Understand the opportunities and challenges of biosampling
  • Biobanking and personalized medicine in oncology
  • Learn the latest technological methods and procedures for biopreservation, storage stability and validation, while naming evidence-based best practices
  • Explore new sample quality management systems, quality standards and accreditation
  • Novel IT solutions, effective data storage, processing and analysis
  • Learn how to maintain a sustainable infrastructure in biobanking
  • Debate the social and ethical challenges of biobanking for human research
  • Predict the market impact of biobanking in the next decade
  • Current market trends and future challenges for biobanking success
  • Biobanking development in emerging markets
  • Prognosis for the Global Biobanking market in an era of transformative new technologies
  • Returning Genetic Results in a Population Cohort
  • Redesigning the biobanking business model
  • Clinical Trial Strategies in Biobanking and Drug Development
  • Starting Materials and Standards for Stem Cell-based Therapies

Who Should Attend?

Delegates typically include CEOs, VPs, Drug developers, Academics and Researchers, CROs, Scientists and Medical Doctors of:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Clinical Development
  • Regulatory Affairs
  • Molecular Diagnostics
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Immunology
  • Genomics
  • Insurers
  • Patient Advocates
  • Payers
  • Market Access
  • Commercialization
  • Oncology
  • Non-oncology
  • Rare Diseases
  • Drug Development
  • Research
  • Biopharmaceuticals and Biologics
  • Researchers
  • Molecular Technologies
  • Intellectual property
  • Legislation and Policy Advice
  • Biobanking Researchers
  • Biobanking Faculty Members
  • Biobanking Associations and Societies
  • Training Institutes
  • Cryo storage Companies
  • Data Provacy and Management Companies
  • Security Officers
  • Global Biobanking Companies
  • Business Developers
  • Biobanking investors
  • Lab Managers
  • Drug and Safety Assessment
  • Market Strategy
  • Biopharmaceuticals
  • Clinical Immunology
  • Drug Safety Assessment & Risk Management
  • Population and Disease Based biobanks
  • Bioinnovation
  • Intellectual property
  • Regulatory Affairs
  • Health Economics Principal Scientists
  • Process Control and Analytical Technologies
  • Quality Affairs/ Quality Control
  • Regulatory Affairs
  • Regulatory Compliance
  • Legal Affairs
  • R&D
  • New Product Development
  • Health Economics
  • Process Control and Analytical Technologies